Dr Clair Brooks, Applications Specialist and Matthew Fenn, Head of Business Development, sat down with PMPS Magazine to discuss how patient behaviour can impact the efficacy of orally inhaled products (OIPs) and what can be done to address this issue to help optimise outcomes.
This article is taken from Pharmaceutical Manufacturing and Packing Sourcer April 2024, Inhalation Technology Supplement, pages 28-30. © Samedan Ltd
